Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010123626) CD133 POLYMORPHISMS AND EXPRESSION PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/123626 International Application No.: PCT/US2010/025968
Publication Date: 28.10.2010 International Filing Date: 02.03.2010
IPC:
C12Q 1/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
LENZ, Heinz-Josef [US/US]; US (UsOnly)
UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; 3740 McClintock Avenue, EEB 131 Los Angeles, California 90089-2561, US (AllExceptUS)
Inventors:
LENZ, Heinz-Josef; US
Agent:
KONSKI, Antoinette F.; FOLEY & LARDNER LLP 975 Page Mill Road Palo Alto, California 94304-1013, US
Priority Data:
61/172,67924.04.2009US
Title (EN) CD133 POLYMORPHISMS AND EXPRESSION PREDICT CLINICAL OUTCOME IN PATIENTS WITH CANCER
(FR) UTILISATION DES POLYMORPHISMES ET DE L'EXPRESSION DE CD133 POUR PRÉDIRE L'ISSUE CLINIQUE CONCERNANT DES PATIENTS CANCÉREUX
Abstract:
(EN) The invention provides compositions and methods for aiding in the determination of or determining whether or not a cancer patient is likely to be responsive to a therapy comprising the administration of an anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.
(FR) La présente invention concerne des compositions et des procédés destinés à aider à déterminer si un patient cancéreux est susceptible de réagir à une thérapie comportant l'administration d'une thérapie anti-VEGF, c'est-à-dire une thérapie dirigée contre le facteur de croissance de l'endothélium vasculaire (en anglais: "Vascular Endothelial Growth Factor"). Lorsqu'on a déterminé qu'un patient est susceptible d'être traité avec succès, l'invention offre également des procédés permettant de traiter de tels patients.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)